DEXCOM, INC. (DXCM) Spending and interest coverage
- R&D / revenue · 12 months: Value 12.15%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 3.27%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 12.15% | Research and development expense / revenue. Period ending 2026-06-30. $604.00M ÷ $4.97B × 100 ≈ 12.15% |
| Stock-based compensation / revenue · 12 months | 3.27% | Share-based compensation / revenue. Period ending 2026-06-30. $162.40M ÷ $4.97B × 100 ≈ 3.27% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 604.00M USD | Research and Development Expense |
| Revenue | 4.97B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 162.40M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | 1.14B USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $604.00M | $4.97B | $162.40M | $1.14B | (m) | 12.15% | 3.27% | (m) | (m) |
| 2026-03-31 | $599.20M | $4.82B | $168.70M | $1.03B | (m) | 12.44% | 3.50% | (m) | (m) |
| 2025-12-31 | $599.10M | $4.66B | $159.60M | $911.80M | (m) | 12.85% | 3.42% | (m) | (m) |
| 2025-09-30 | $590.40M | $4.52B | $167.90M | $777.70M | (m) | 13.07% | 3.72% | (m) | (m) |
| 2025-06-30 | $568.30M | $4.30B | $166.20M | $687.20M | (m) | 13.21% | 3.86% | (m) | (m) |
| 2025-03-31 | $556.10M | $4.15B | $165.60M | $632.60M | (m) | 13.41% | 3.99% | (m) | (m) |
| 2024-12-31 | $552.40M | $4.03B | $170.40M | $600.00M | (m) | 13.70% | 4.23% | (m) | (m) |
| 2024-09-30 | $549.00M | $3.95B | $164.00M | $628.00M | (m) | 13.88% | 4.15% | (m) | (m) |
| 2024-06-30 | $545.00M | $3.93B | $159.60M | $681.50M | (m) | 13.85% | 4.06% | (m) | (m) |
| 2024-03-31 | $528.30M | $3.80B | $154.60M | $651.60M | $20.30M | 13.90% | 4.07% | 32.10× | Reported |
| 2023-12-31 | $505.80M | $3.62B | $150.80M | $597.70M | $20.30M | 13.96% | 4.16% | 29.44× | Reported |
| 2023-09-30 | $486.00M | $3.40B | $147.90M | $506.20M | $20.10M | 14.28% | 4.35% | 25.18× | Reported |
| 2023-06-30 | $464.90M | $3.20B | $139.70M | $448.20M | $19.80M | 14.54% | 4.37% | 22.64× | Reported |
| 2023-03-31 | $467.30M | $3.02B | $132.60M | $397.10M | $18.60M | 15.46% | 4.39% | 21.35× | Reported |
| 2022-12-31 | $484.20M | $2.91B | $126.50M | $391.20M | $18.60M | 16.64% | 4.35% | 21.03× | Reported |
| 2022-09-30 | $517.70M | $2.79B | $118.80M | $266.40M | $100.10M | 18.54% | 4.25% | 2.66× | Reported |
| 2022-06-30 | $536.20M | $2.67B | $115.50M | $237.20M | $100.10M | 20.06% | 4.32% | 2.37× | Reported |
| 2022-03-31 | $543.60M | $2.57B | $114.50M | $261.20M | $100.20M | 21.13% | 4.45% | 2.61× | Reported |
| 2021-12-31 | $517.10M | $2.45B | $113.40M | $265.80M | $100.30M | 21.12% | 4.63% | 2.65× | Reported |
| 2021-09-30 | $486.50M | $2.32B | $121.20M | $369.20M | $99.70M | 20.98% | 5.23% | 3.70× | Reported |
| 2021-06-30 | $445.40M | $2.17B | $124.40M | $345.00M | $99.00M | 20.53% | 5.73% | 3.48× | Reported |
| 2021-03-31 | $396.20M | $2.03B | $123.50M | $311.80M | $94.10M | 19.55% | 6.09% | 3.31× | Reported |
| 2020-12-31 | $359.90M | $1.93B | $119.40M | $299.50M | $84.70M | 18.68% | 6.20% | 3.54× | Reported |
| 2020-09-30 | $319.50M | $1.82B | $108.90M | $297.00M | $75.40M | 17.55% | 5.98% | 3.94× | Reported |
| 2020-06-30 | $298.50M | $1.72B | $102.60M | $258.90M | $66.10M | 17.40% | 5.98% | 3.92× | Reported |
| 2020-03-31 | $287.60M | $1.60B | $101.60M | $190.30M | $60.80M | 17.97% | 6.35% | 3.13× | Reported |
| 2019-12-31 | $273.50M | $1.48B | $102.70M | $142.30M | $60.30M | 18.53% | 6.96% | 2.36× | Reported |
| 2019-09-30 | $252.30M | $1.35B | $103.70M | $-123.80M | $53.20M | 18.67% | 7.67% | -2.33× | Reported |
| 2019-06-30 | $235.70M | $1.22B | $106.40M | $-165.90M | $43.00M | 19.29% | 8.71% | -3.86× | Reported |
| 2019-03-31 | $213.90M | $1.13B | $102.30M | $-170.00M | $32.80M | 18.97% | 9.07% | -5.18× | Reported |
| 2018-12-31 | $199.70M | $1.03B | $101.90M | $-186.30M | $22.70M | 19.36% | 9.88% | -8.21× | Reported |
| 2018-09-30 | $190.80M | $914.60M | $102.20M | $-9.70M | $19.20M | 20.86% | 11.17% | -0.51× | Reported |
| 2018-06-30 | $184.00M | $832.50M | $100.50M | $-24.10M | $18.80M | 22.10% | 12.07% | -1.28× | Reported |
| 2018-03-31 | $182.10M | $760.60M | $100.20M | $-32.80M | $17.10M | 23.94% | 13.17% | -1.92× | Reported |
| 2017-12-31 | $185.40M | $718.50M | $106.20M | $-42.50M | $12.80M | 25.80% | 14.78% | -3.32× | Reported |
| 2017-09-30 | $180.40M | $668.70M | $110.40M | $-60.60M | $8.40M | 26.98% | 16.51% | -7.21× | Reported |
| 2017-06-30 | $181.00M | $632.70M | $114.00M | $-78.60M | $4.10M | 28.61% | 18.02% | -19.17× | Reported |
| 2017-03-31 | $172.00M | $599.40M | $116.30M | $-85.10M | $1.10M | 28.70% | 19.40% | -77.36× | Reported |
| 2016-12-31 | $156.10M | $573.30M | $110.80M | $-63.90M | $700.00K | 27.23% | 19.33% | -91.29× | Reported |
| 2016-09-30 | $140.90M | $532.90M | $105.20M | $-56.20M | $400.00K | 26.44% | 19.74% | -140.50× | Reported |
| 2016-06-30 | $161.80M | $489.50M | $98.80M | $-80.10M | $300.00K | 33.05% | 20.18% | -267.00× | Reported |
| 2016-03-31 | $149.90M | (m) | $91.90M | $-63.60M | $300.00K | (m) | (m) | -212.00× | Reported |
| 2015-12-31 | $137.50M | $402.00M | $82.70M | $-57.10M | $400.00K | 34.20% | 20.57% | -142.75× | Reported |
| 2015-09-30 | $130.60M | $355.50M | $73.50M | $-57.10M | $600.00K | 36.74% | 20.68% | -95.17× | Reported |
| 2015-06-30 | $84.30M | $319.30M | $64.70M | $-19.70M | $700.00K | 26.40% | 20.26% | -28.14× | Reported |
| 2015-03-31 | $74.70M | $284.90M | $57.20M | $-21.90M | $800.00K | 26.22% | 20.08% | -27.38× | Reported |
| 2014-12-31 | $69.40M | $259.20M | $50.00M | $-21.50M | $800.00K | 26.77% | 19.29% | -26.88× | Reported |
| 2014-09-30 | $60.40M | $226.60M | $42.30M | $-25.40M | $900.00K | 26.65% | 18.67% | -28.22× | Reported |
| 2014-06-30 | $53.70M | $200.50M | $35.10M | $-26.20M | $900.00K | 26.78% | 17.51% | -29.11× | Reported |
| 2014-03-31 | $50.00M | $177.50M | $28.30M | $-30.30M | $900.00K | 28.17% | 15.94% | -33.67× | Reported |
| 2013-12-31 | $44.80M | $160.00M | $24.60M | $-28.90M | $900.00K | 28.00% | 15.38% | -32.11× | Reported |
| 2013-09-30 | $42.00M | $141.60M | $22.50M | $-34.90M | $800.00K | 29.66% | 15.89% | -43.63× | Reported |
| 2013-06-30 | $40.40M | $121.80M | $20.80M | $-46.40M | $600.00K | 33.17% | 17.08% | -77.33× | Reported |
| 2013-03-31 | $39.40M | $109.40M | $19.30M | $-51.20M | $400.00K | 36.01% | 17.64% | -128.00× | Reported |
| 2012-12-31 | $39.50M | $99.90M | $18.40M | $-55.70M | $200.00K | 39.54% | 18.42% | -278.50× | Reported |
| 2012-09-30 | $40.03M | $89.06M | $17.44M | $-59.64M | $3.00K | 44.95% | 19.58% | -19881.33× | Reported |
| 2012-06-30 | $37.68M | $84.22M | $16.29M | $-55.63M | $3.00K | 44.74% | 19.34% | -18543.33× | Reported |
| 2012-03-31 | $34.19M | $82.19M | $15.11M | $-48.37M | $5.00K | 41.61% | 18.39% | -9674.00× | Reported |
| 2011-12-31 | $30.75M | $76.27M | $13.51M | $-44.84M | $11.00K | 40.32% | 17.72% | -4076.64× | Reported |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | $53.26M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | $23.23M | $48.63M | $9.44M | $-45.29M | $1.55M | 47.76% | 19.41% | -29.26× | Reported |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | $14.29M | $29.69M | $8.37M | $-45.83M | $8.04M | 48.14% | 28.17% | -5.70× | Reported |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| WEST PHARMACEUTICAL SERVICES INC (WST) | United States | $26.288B | 43.14 |
| BECTON DICKINSON & CO (BDX) | United States | $48.834B | 43.79 |
| Solventum Corp (SOLV) | United States | $15.085B | 9.16 |
| Penumbra Inc (PEN) | United States | $12.596B | 77.33 |
| BAXTER INTERNATIONAL INC (BAX) | United States | $12.139B | -10.35 |
| GLOBUS MEDICAL INC (GMED) | United States | $9.977B | 20.03 |
| INSULET CORP (PODD) | United States | $9.420B | 28.12 |
| GLAUKOS Corp (GKOS) | United States | $9.135B | -43.73 |
| MiniMed Group, Inc. (MMED) | United States | $5.748B | -16.85 |
| MERIT MEDICAL SYSTEMS INC (MMSI) | United States | $5.212B | 28.44 |